老虎证券

US FDA extends review of Travere’s drug for rare kidney disease

Reuters
01/14
US FDA extends review of Travere’s drug for rare kidney disease

Jan 13 (Reuters) - The U.S. Food and Drug Administration has extended its review for the expanded use of Travere Therapeutics’TVTX.O drug to treat a type of rare kidney disorder, the drugmaker said on Tuesday.

The agency will now give its decision on April 13, compared to its previous action date of January 13.

(Reporting by Sahil Pandey and Siddhi Mahatole in Bengaluru; Editing by Sahal Muhammed)

((Sahil.Pandey@thomsonreuters.com;))

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10